METTL3 and hepatocellular carcinoma: Consistently, the results of CCK8 cell growth assay in HCCs with METTL3 knockdown (Appendix Fig S2R and S) or sorafenib resistance (Appendix Fig S2T) showed a similar rescuing tendency, as well as a cell survival assay in sorafenib‐resistant HepG‐2 cells (Fig 2J), indicating the important role of the m6A modification mediated by METTL3 in sorafenib resistance in HCC.